Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Axim Biotechnologies Inc (AXIM)
Axim Biotechnologies Inc (AXIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AXIM with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0130 +35.38%
on 03/01/24
0.0194 -9.28%
on 02/21/24
-0.0018 (-9.28%)
since 02/02/24
3-Month
0.0130 +35.38%
on 03/01/24
0.0215 -18.14%
on 12/15/23
-0.0024 (-12.00%)
since 12/04/23
52-Week
0.0130 +35.38%
on 03/01/24
0.0600 -70.67%
on 03/21/23
-0.0022 (-11.11%)
since 03/03/23

Most Recent Stories

More News
AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international...

AXIM : 0.0176 (+13.55%)
AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international...

AXIM : 0.0176 (+13.55%)
AXIM Launches New Eye Care Website; Establishes Platform for Commercialization

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international...

AXIM : 0.0176 (+13.55%)
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international...

AXIM : 0.0176 (+13.55%)
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international...

AXIM : 0.0176 (+13.55%)
AXIM Biotechnologies CEO Issues Letter to Shareholders

Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic systemPlans to address largely underserved DED...

AXIM : 0.0176 (+13.55%)
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international...

AXIM : 0.0176 (+13.55%)
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch

AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s...

AXIM : 0.0176 (+13.55%)
CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies

SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international...

AXIM : 0.0176 (+13.55%)
AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests

Company’s first rapid test to measure neutralizing antibodies is currently under FDA review...

AXIM : 0.0176 (+13.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0207
2nd Resistance Point 0.0191
1st Resistance Point 0.0184
Last Price 0.0176
1st Support Level 0.0161
2nd Support Level 0.0145
3rd Support Level 0.0138

See More

52-Week High 0.0600
Fibonacci 61.8% 0.0420
Fibonacci 50% 0.0365
Fibonacci 38.2% 0.0310
Last Price 0.0176
52-Week Low 0.0130

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar